Industry News
Pharmaceutical Industry News
The FDA is providing more insight…
The FDA is providing more insight into the rejections it recently handed two pharma giants, publishing the complete response letters (CRLs) sent to AstraZeneca and GSK that highlight shortfalls in the data included in their
Novo will invest 432 million euros…
Novo will invest 432 million euros ($501 million) to add a new tableting plant at its facility in Athlone, Ireland, the company said in a March 2 press release. The expansion will equip the Athlone
Esperion has acquired Corstasis…
Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago. Esperion paid $75 million upfront and earmarked $180 million for potential milestones while agreeing to pay
As Kennedy Turns From Vaccines, MAHA Allies See a ‘Betrayal’
As the midterm elections approach, the health secretary is focusing on “real food.” Anger is rising among some of his supporters.
States Move to Limit Access to H.I.V. Treatment
Citing rising costs and shortfalls in federal support, about 20 states are toughening eligibility requirements for patients in drug assistance programs.
As it ramps up its rollout of the…
As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.
Since GLP-1 blockbusters…
Since GLP-1 blockbusters semaglutide and tirzepatide broke into the mainstream for their ability to treat diabetes and provoke weight loss, evidence has been piling up that the molecules can reduce the risk of heart problems
As the effects of the United…
As the effects of the United States and Israel’s weekend attack on Iran begin to ripple through the Middle East, multiple drugmakers operating in the region are taking stock of their local workforces’ safety and
The newest additions to the CDC’s…
The newest additions to the CDC's vaccine advisory committee are Florida internal medicine and pediatrics specialist Sean G. Downing, M.D., and pediatrician Angelina Farella, M.D.
With some 12 years as CEO under…
With some 12 years as CEO under his belt, Bavarian Nordic’s Paul Chaplin is telegraphing his exit from the Denmark-based vaccine maker. The planned move comes shortly after another high-profile exit at the company, with
Ascendis Pharma is spiraling…
Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based biopharma has scored an FDA approval for a rare disease medicine that was developed with
Quotient Sciences, a CDMO that…
Quotient Sciences, a CDMO that specializes in "niche and smaller volume" drugs, has extended a deal with Ipsen to manufacture Sohonos (palovarotene) capsules. Sohonos is currently the only medication approved by the FDA to treat
Henrietta Lacks’s Family Settles Suit With Novartis Over Use of Her Cells
Ms. Lacks’s family accused Novartis of profiting from her cells, which were taken from her without her consent in 1951, when she was dying of cervical cancer.
Several Big Pharmas have…
Several Big Pharmas have introduced their own podcasts to advance corporate branding efforts, while health-focused nonprofits have found in podcasts an effective awareness-raising tool with a relatively low barrier of entry in terms of production
In a Worker Adjustment and…
In a Worker Adjustment and Retraining Notification Act alert filed this week, Merck revealed that it is laying off 147 staffers at a vaccine manufacturing plant in Durham. The cuts are a result of Merck's
A handful of pharmas and…
A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation for a long-lasting awareness push.
While the FDA has flip-flopped on…
While the FDA has flip-flopped on whether to review Moderna’s combination influenza/COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe, with a positive recommendation from the CHMP.
Two years and five indications…
Two years and five indications later, UCB's immunology blockbuster Bimzelx is halfway to the company's initial goal of at least 4 billion euros ($4.4 billion) in peak sales.
As one long-running feud over the…
As one long-running feud over the controversial generic drug carve-out known as “skinny” labeling comes to a close, the U.S.’ top lawyer is urging the Supreme Court to reverse a recent decision on another, arguing
China assets have outgrown a…
China assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, Evaluate said. Daiichi Sankyo named former Novartis exec John Tsai, M.D., as its new R&D head.